Prostate Cancer - Results from #220

Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide. April 18, 2023

Feasibility, acceptability, and behavioral outcomes of a multimodal intervention for prostate cancer patients: Experience from the MARTINI lifestyle program. April 18, 2023

A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. April 18, 2023

Multi-Institutional Clinical Outcomes of Biopsy Gleason Grade Group 5 Prostate Cancers Treated With Contemporary High-Dose Radiation and Long-Term Androgen Deprivation Therapy. April 18, 2023

Is there more than meets the eye in PSMA imaging in prostate cancer with PET/MRI? Looking closer at uptake time, correlation with PSA and Gleason score. April 18, 2023

Adaptive Immunity in Genitourinary Cancers. April 18, 2023

Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy. April 17, 2023

Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma. April 17, 2023

Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. April 17, 2023

Tumor testing and treatment patterns in veterans with metastatic castration-resistant prostate cancer. April 17, 2023

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer. April 17, 2023

Metastatic Sites’ Location and Impact on Patient Management After the Introduction of Prostate-specific Membrane Antigen Positron Emission Tomography in Newly Diagnosed and Biochemically Recurrent Prostate Cancer: A Critical Review April 14, 2023

Magnetic Resonance Imaging–guided Focal Boost to Intraprostatic Lesions Using External Beam Radiotherapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis April 14, 2023

Integrated single-cell analysis defines the epigenetic basis of castration-resistant prostate luminal cells. April 14, 2023

Analysis of evolutionary dynamics and clonal architecture in prostate cancer. April 14, 2023

Development and External Validation of a Novel Nomogram to Predict the Probability of Pelvic Lymph-node Metastases in Prostate Cancer Patients Using Magnetic Resonance Imaging and Molecular Imaging with Prostate-specific Membrane Antigen Positron Emission April 14, 2023

Risk Stratification of Low-Risk Prostate Cancer: Individualizing Care in the Era of Active Surveillance. April 14, 2023

Identifying Men Who Can Remain on Active Surveillance Despite Biopsy Reclassification to Grade Group 2 Prostate Cancer. April 14, 2023

A DNA copy number alteration classifier as a prognostic tool for prostate cancer patients. April 13, 2023

External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. April 13, 2023

Page 12 of 1305